Details
Stereochemistry | RACEMIC |
Molecular Formula | C16H18O3 |
Molecular Weight | 258.3123 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C(O)=O)C1=CC=C(\C=C2/CCCCC2=O)C=C1
InChI
InChIKey=AUZUGWXLBGZUPP-GXDHUFHOSA-N
InChI=1S/C16H18O3/c1-11(16(18)19)13-8-6-12(7-9-13)10-14-4-2-3-5-15(14)17/h6-11H,2-5H2,1H3,(H,18,19)/b14-10+
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/21809372Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25403311
http://adisinsight.springer.com/trials/700254420
https://www.daewonpharm.com/en/products/2_3medicine2.jsp?cd=EC11&PRD_NO=300
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21809372
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25403311
http://adisinsight.springer.com/trials/700254420
https://www.daewonpharm.com/en/products/2_3medicine2.jsp?cd=EC11&PRD_NO=300
Pelubiprofen, 2-[4-(Oxocyclohexylidene methyl)phenyl]propionic acid, is one of the 2-arylpropionic acid class of non-steroidal anti-inflammatory drugs (NSAIDs). It has wide variety of indications proposed: osteoarthritis, rheumatoid arthritis, musculoskeletal pain, post-operative trauma, backache, neck-shoulder syndrome and dental pain. Pelubiprofen is a prodrug of 2-arylpropionic acid with relatively selective effects on cyclooxygenase-2 activity. Antiinflammatory properties of pelubiprofen are due to its ability to both decrease prostaglandin synthesis by inhibiting the activities of cyclooxygenases (COXs) and IkB kinase-b (IKK-b). Pelubiprofen was found to have an anti-edema effect in the carrageenan-induced paw edema model in rats, one of the well-established acute inflammatory models in vivo. Pelubiprofen was well tolerated in single doses up to 120mg and at a dosage of 180 mg/day. No drug accumulation was evident, suggesting that it may be useful for long term treatment.
Originator
Sources: http://adisinsight.springer.com/drugs/800000947
Curator's Comment: Sankyo (http://www.daiichisankyo.com/) discontinued its own development of pelubiprofen and licensed the product to Daewon Pharmaceutical Co., Ltd..
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P35354 Gene ID: 5743.0 Gene Symbol: PTGS2 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/25403311 |
2.88 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Primary | Pelubi Approved UseReduce symptom of Osteoarthritis, Back pain (Lumbago) |
|||
Primary | Pelubi Approved UseReduce symptom of Osteoarthritis, Back pain (Lumbago) |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21809372
RAW 264.7 mouse macrophage cell line. Pelubiprofen potently diminished PGE2 productions through inhibition of COX enzyme activity (IC50 values for COX-1 and COX-2 are 10.66 +/-0.99 and 2.88 +/-1.01 uM, respectively), but also reduced the expressions of COX-2, inducible nitric oxide (iNOS), tumor necrosis factor-a (TNF-a), interleukin-1b (IL-1b), and IL-6 at transcriptional level in LPS-induced RAW 264.7 cells. Pelubiprofen attenuated the LPS-induced transcription activity and the DNA binding activity of NF-kB, which was accompanied by a parallel reduction of degradation and phosphorylation of inhibitory kappa B-a (IkB-a) and consequently by decreased nuclear translocation of NF-kB. Pelubipofen inhibited the LPS-induced phosphorylation of IKK-b and transforming growth factor-b activated kinase-1 (TAK1).
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 16:11:19 GMT 2023 , Edited by admin on Fri Dec 15 16:11:19 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
7536
Created by
admin on Fri Dec 15 16:11:19 GMT 2023 , Edited by admin on Fri Dec 15 16:11:19 GMT 2023
|
PRIMARY | |||
|
DTXSID2048795
Created by
admin on Fri Dec 15 16:11:19 GMT 2023 , Edited by admin on Fri Dec 15 16:11:19 GMT 2023
|
PRIMARY | |||
|
CHEMBL69308
Created by
admin on Fri Dec 15 16:11:19 GMT 2023 , Edited by admin on Fri Dec 15 16:11:19 GMT 2023
|
PRIMARY | |||
|
5282203
Created by
admin on Fri Dec 15 16:11:19 GMT 2023 , Edited by admin on Fri Dec 15 16:11:19 GMT 2023
|
PRIMARY | |||
|
100000082494
Created by
admin on Fri Dec 15 16:11:19 GMT 2023 , Edited by admin on Fri Dec 15 16:11:19 GMT 2023
|
PRIMARY | |||
|
1619C79FVJ
Created by
admin on Fri Dec 15 16:11:19 GMT 2023 , Edited by admin on Fri Dec 15 16:11:19 GMT 2023
|
PRIMARY | |||
|
C040375
Created by
admin on Fri Dec 15 16:11:19 GMT 2023 , Edited by admin on Fri Dec 15 16:11:19 GMT 2023
|
PRIMARY | |||
|
DB12150
Created by
admin on Fri Dec 15 16:11:19 GMT 2023 , Edited by admin on Fri Dec 15 16:11:19 GMT 2023
|
PRIMARY | |||
|
69956-77-0
Created by
admin on Fri Dec 15 16:11:19 GMT 2023 , Edited by admin on Fri Dec 15 16:11:19 GMT 2023
|
PRIMARY | |||
|
SUB09652MIG
Created by
admin on Fri Dec 15 16:11:19 GMT 2023 , Edited by admin on Fri Dec 15 16:11:19 GMT 2023
|
PRIMARY | |||
|
C66333
Created by
admin on Fri Dec 15 16:11:19 GMT 2023 , Edited by admin on Fri Dec 15 16:11:19 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD